Novo Nordisk Stages Pre-ADA Rally as Oral Wegovy Lands in UAE and Pipeline Bets Intensify

Novo Nordisk stock gains ~3.5% as oral Wegovy launches in UAE, Goldman Sachs raises price target, and investors await ADA conference updates on next-gen obesity treatments.

Novo Nordisk shares recouped some ground on Thursday as a dense cluster of corporate catalysts — from the first international launch of its oral Wegovy pill to a slate of scientific presentations at the American Diabetes Association’s annual meeting — drew buyers back into the stock. The Danish drugmaker closed the session between EUR 37.59 and EUR 37.67, a gain of roughly 3.3% to 3.5%, depending on the data feed. The move pushed the equity roughly 5% to 5.5% above its 50-day moving average, a modest technical victory after a punishing stretch that has left the share price nearly 46% below the 52-week high of EUR 70.13 set last June.

The most tangible near-term catalyst came from outside the conference halls. Novo Nordisk has taken its oral formulation of semaglutide — sold as Wegovy — to the United Arab Emirates, its first market outside the United States. The company cited local demand and the region’s existing healthcare infrastructure as drivers of the choice. The pill’s efficacy, drawn from the OASIS-4 study, showed that consistent users shed roughly 17% of their body weight. Additional markets are expected in the second half of 2026, though specific countries have not been disclosed. The move comes as U.S. pharmacy benefit managers have expanded coverage of competing GLP-1 products, pressuring Novo to diversify geographically.

Goldman Sachs analyst James Quigley responded to the strong early prescription data for the oral pill by lifting his price target on Novo Nordisk shares to DKK 305 from DKK 263, while maintaining a Neutral rating. The drug accumulated 1.3 million prescriptions in the first quarter on the U.S. market and another 1.1 million in the first six weeks of the second quarter. Quigley described the launch speed as unusually rapid, strengthening Novo’s competitive position in obesity care.

Meanwhile, the company’s foundation parent, Novo Holdings, committed EUR 500 million as a founding investor in the Scaleup Europe Fund, a pan-European growth vehicle targeting technology and healthcare companies in late growth stages. The fund aims to reach a total volume of up to EUR 5 billion.

Attention now shifts to the American Diabetes Association conference, which begins on Friday. Novo Nordisk has scheduled a dedicated development day for investors on Sunday, where analysts expect detailed updates on next-generation obesity treatments and the broader cardiometabolic pipeline. Just last week, the company initiated a first-in-human, placebo-controlled trial for a new injectable candidate, NNC0113-5840, in overweight subjects — a sign that Novo is pushing to broaden its portfolio beyond the dominant GLP-1 class.

In parallel, Novo Nordisk has signed a clinical supply agreement with Veru Inc. Under the deal, Novo will provide Wegovy free of charge for Veru’s Phase 2b PLATEAU study, which tests a combination of enobosarm and semaglutide. Veru retains sponsorship and global marketing rights, but Novo secures a first right of negotiation for a potential co-development.

From a chart perspective, the next technical milestone sits at the 100-day moving average of EUR 38.37. Convincing pipeline data at the Sunday investor day could propel the stock toward that level. Disappointment, however, carries the risk of a rapid retreat to the March low. For now, Novo Nordisk is presenting a multi-fronted case to investors: a newly globalized oral Wegovy, a deepening clinical pipeline, and a strategic capital commitment from its largest shareholder — all converging in a single, high-stakes week.